Details of the Drug Reposition

General Information of This Drug (ID: DMERJ19)

Drug Name
NX-1207   DMERJ19
Synonyms
UNII-9L8TV1O7E0; 9L8TV1O7E0; Fexapotide [USAN]; CHEMBL3545061; 492447-54-8; L-Leucine, L-isoleucyl-L-alpha-aspartyl-L-glutaminyl-L-glutaminyl-L-valyl-L-leucyl-L-seryl-L-arginyl-L-isoleucyl-L-lysyl-L-leucyl-L-alpha-glutamyl-L-isoleucyl-L-lysyl-L-arginyl-L-cysteinyl-; L-isoleucyl-L-alpha-aspartyl-L-glutaminyl-L-glutaminyl-L-valyl-L-leucyl-L-seryl-L-arginyl-L-isoleucyl-L-lysyl-L-leucyl-L-alpha-glutamyl-L-isoleucyl-L-lysyl-L-arginyl-L-cysteinyl-L-leucine-
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Hepatocellular carcinoma DIS0J828 2C12.02 Phase 3 [1]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Prostate cancer DISF190Y 2C82.0 Phase 2 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02003742) Efficacy and Safety of a Single TRUS-guided Intraprostatic Injection of NX-1207 in Patients With LUTS Due to BPH. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)